If you have been reading about insulin-like growth factor 1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-10. Numbers and descriptions here follow the published literature rather than marketing material.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
| Property | Value | Notes |
|---|---|---|
| Primary marker | Insulin-like growth factor 1 | Slow-changing integrated indicator of axis activity |
| Secondary marker | Growth hormone | Pulsatile; requires repeated or timed sampling |
| Typical analytical method | Immunoassay | Antibody-based quantification in serum |
| Common sample matrix | Serum | Collected under standardized conditions |
| Key interpretation factor | Age-stratified reference ranges | Baseline marker concentrations shift with age |
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
=== Distribution, phenology, and ecology === Fungarium records provide a historical record of global biodiversity that can be linked to environmental change. Georeferenced metadata allow researchers to connect specimens to historical climate and land-use databases such as WorldClim. Analysis of collection dates in Europe has revealed delays in the autumnal fruiting season and a general widening of the season for saprotrophic fungi. Specimens have also been used to trace invasive species; for example, the introduction and spread of Amanita phalloides in the western United States was reconstructed using DNA from collections spanning a century. Stable carbon and nitrogen isotope analysis of sporocarps in the genus Ramaria has confirmed their nutritional modes and roles in carbon cycling. Although many historical records lack geographic coordinates or contain only vague locality descriptions, retrospective georeferencing can make older specimens more useful for spatial analyses such as species distribution modelling, provided the associated uncertainty is documented.
To gain regulatory approval, the milbemycin oxime/lufenuron heartworm treatment was divested to Virbac. In March 2015, the company announced it would join Hanmi Pharmaceutical in developing and commercializing Hanmi's phase I Bruton's tyrosine kinase inhibitor HM71224 in a deal that could yield $690 million. A day later, however, the company announced another deal with China's Innovent Biologics to co-develop and commercialize at least three of Innovent's treatments over the next decade, in a deal which could generate up to $456 million; the collaboration was subsequently expanded in 2022, according to Innovent. As part of the deal, the company contributed its c-Met monoclonal antibody, and Innovent contributed a monoclonal antibody, which targets CD-20. The second compound from Innovent is a preclinical immunooncology molecule. The following week, the company announced it would restart its collaboration with Pfizer surrounding the Phase III trial of Tanezumab. Pfizer is expected to receive an upfront sum of $200 million from the company. In April 2015, Lilly engaged CBRE Group to sell its biomanufacturing facility in Vacaville, California, a 52 acres (0.21 km2) campus and facility that is one of the largest biopharmaceutical manufacturing centers in the US. In July 2016, Lechleiter retired and was succeeded by David Ricks. In January 2017, Elanco, at the time a subsidiary of Lilly, acquired Boehringer Ingelheim Vetmedica, a subsidiary of Boehringer Ingelheim's US feline, canine, and rabies vaccines portfolio, for $885 million.
Until World War II, Americans drank equal amounts of green tea and black tea. The war cut off green tea shipments from China and Japan, so Americans turned to the mostly black tea traded by the British Empire from India and Sri Lanka. After the war, 99 percent of the tea in America was black. The American specialty tea market has quadrupled in the years from 1993 to 2008, now being worth $6.8 billion a year. Specialty tea houses and retailers also started to pop up during this period.
==== Kenya ==== In February 2022, the company announced an agreement to build a distribution center in Chemelil, Kisumu County. and began in October that year, as well as medical supplies it delivers veterinary goods and animal DNA, it serves 1012 facilities within the surrounding Region.
Sources: en.wikipedia.org
==== Electrochemical fluorination ==== Electrochemical fluorination (ECF) (also known as the Simons' process) involves electrolysis of a substrate dissolved in hydrogen fluoride. As fluorine is itself manufactured by the electrolysis of hydrogen fluoride, ECF is a rather more direct route to fluorocarbons. The process proceeds at low voltage (5 – 6 V) so that free fluorine is not liberated. The choice of substrate is restricted as ideally it should be soluble in hydrogen fluoride. Ethers and tertiary amines are typically employed. To make perfluorohexane, trihexylamine is used, for example:
== Principle == Many organic molecules contain multiple functional groups that may react under similar conditions. Protecting groups are therefore introduced temporarily to prevent unwanted reactions during synthesis. In an orthogonal protecting group strategy, different protecting groups are chosen so that each responds to a specific set of reaction conditions. For example, one protecting group may be removed by acidic conditions, while another may be removed by basic conditions. Because the removal of one group does not affect the other, the two groups are considered orthogonal.
== Interactions == Few pharmacokinetic drug interactions have been demonstrated in vivo. The manufacturer notes potential pharmacological interactions with opioids, benzodiazepines, barbiturates, ethanol (alcohol), and other central nervous system depressants. Concurrent use of ACE inhibitors and pregabalin may increase the risk of angioedema. Pregabalin may also enhance the fluid-retaining effects of certain antidiabetic agents, such as thiazolidinediones. Pregabalin may independently increase the risk of angioedema, and this risk is further elevated when used in combination with other drugs known to increase the likelihood of angioedema. These drugs include, but are not limited to, certain L-type calcium channel blockers, ACE inhibitors, angiotensin II receptor blockers, and other agents that inhibit the renin–angiotensin–aldosterone system. The combination of pregabalin with opioids is associated with an increased risk of respiratory depression. This interaction reflects both pharmacodynamic and pharmacokinetic mechanisms: pharmacodynamically, pregabalin and opioids produce additive CNS depression, while pharmacokinetically, opioids reduce gastrointenstinal motility, which may prolong gabapentin absorption and raise its plasma concentrations, with a 2017 study finding that use of gabapentin alongside opioids carries an increased risk of opioid-related death. As pregabalin and gabapentin share the same mechanism of action (binding to the α2δ subunit of voltage-gated calcium channels), findings regarding gabapentin are considered likely applicable to pregabalin.
Sources: en.wikipedia.org
A similar resemblance has been noted by Joanna Jurewicz, who argues that the first four nidanas resemble the Hymn of Creation (RigVeda X, 12) and other Vedic sources which describe the creation of the cosmos. Jurewicz argues that dependent origination is "a polemic" against the Vedic creation myth and that, paradoxically, "the Buddha extracted the essence of Vedic cosmogony and expressed in explicit language." Richard Gombrich agrees with this view, and argues that the first four elements of dependent origination are the Buddha's attempt to "ironize and criticize Vedic cosmogony." According to Gombrich, while in the Vedic creation theory "the universe is considered to be grounded on a primordial essence which is endowed with consciousness," the Buddha's theory avoids this essence (atman-Bahman). Jurewicz and Gombrich compare the first nidana, ignorance (avijja), with the stage before creation that is described in the Rigveda's Hymn of Creation. While the term avidya does not actually appear in this Hymn, the pre-creation stage is seen as unknowable and characterized by darkness. According to Gombrich, at this stage "consciousness is non-dual, which is to say that it is the ability to cognize but not yet consciousness of anything, for there is no split yet into subject and object." This is different from the Buddha's point of view, in which consciousness is always consciousness of something. Jurewicz then compares the Vedic creator's desire and hunger to create the atman (or "his second self") with volitional impulses (samskara).
Facilitated diffusion is the passage of molecules or ions across a biological membrane through specific transport proteins and requires no energy input. Facilitated diffusion is used especially in the case of large polar molecules and charged ions; once such ions are dissolved in water they cannot diffuse freely across cell membranes due to the hydrophobic nature of the fatty acid tails of the phospholipids that make up the bilayers. The type of carrier proteins used in facilitated diffusion is slightly different from those used in active transport. They are still transmembrane carrier proteins, but these are gated transmembrane channels, meaning they do not internally translocate, nor require ATP to function. The substrate is taken in one side of the gated carrier, and without using ATP the substrate is released into the cell. Facilitated diffusion does not require the use of ATP as facilitated diffusion, like simple diffusion, transports molecules or ions along their concentration gradient.
A particular challenge in analysing AlphaFold models is distinguishing genuine topology from structural prediction artefacts. A high confidence score does not by itself guarantee that a predicted chain crossing is correct, and incorrect modelling of termini or flexible regions may change the calculated topology. AlphaKnot 2.0 therefore provides several measures intended to help evaluate a predicted knot, including the pLDDT values of the complete chain and knot core, the confidence near the boundaries of the knot core, and detection of unusually close contacts between Cα atoms. Users can also compare AlphaFold predictions with independently generated ESMFold models for shorter proteins. Because automated analysis at the scale of the AlphaFold database cannot be manually verified structure by structure, AlphaKnot 2.0 introduced a user annotation system. Database entries can be assessed by users as a knot, artifact, or unsure, allowing potentially incorrect predictions to be flagged for further consideration.
Sources: en.wikipedia.org
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.
Assay calibration and antibody specificity differ between platforms, so identical samples can yield different numbers. A method change within one laboratory can shift results without any biological change. Cross-validation is often needed for multi-site work.
They capture only one moment in a pulsatile pattern and are strongly influenced by recent activity and meals. Repeated sampling or overnight profiles provide a more representative view. Provocative testing is an alternative when a dynamic response is of interest.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.